Mostly Markets
Subscribe
Stocks/Health Care/Biotechnology

Gilead SciencesGILD

Biotechnology · Foster City, California · In the S&P 500
Solid business
$170.68+3.06%After hours: $170.73 (+0.03%)At the close, 30 Oct · Prices from CNBC, may be delayed
▲ 44.0% over 1 year
Gilead Sciences over 1 yearDaily close, $, to 30 Oct 2026
$120$140$160Nov2026MarMayJulSep$170.68$120$140$160NovMarJul$170.68
Source: Nasdaq daily closes
Market value$212B
Price to earnings–
Forward P/E19.4x
Dividend yield1.92%
Year to date+39.1%
One year+44.0%
Next earningsNot scheduled
SectorHealth Care
52-week range (closes)
$118.15$170.68

Quality and valuation

How Gilead Sciences compares with other health care stocks. A description, not a recommendation.

Gilead Sciences and 7 biotechnology peers. Across: valuation (P/E) against the sector. Up: business quality against the sector. Hover or tap a logo for its numbers.

Business quality: about averageValuation: in line with its sector

An average business among health care companies, priced about in line with them.

Gilead Sciences trades at 19.4 times the next 12 months of expected earnings, against a median of 19.1x for the 65 health care stocks we cover. The quality score blends where it ranks on revenue growth, gross margin, operating margin and free-cash-flow margin (net margin for banks and insurers) over the last 12 months, from SEC filings.

  • Revenue grew slower than the sector median: +6.5% vs +7.8%
  • Keeps more of each sale (gross margin): 79.9% vs 65.3%
  • Less profitable (operating margin): −7.6% vs 13.3%
  • Turns more of its sales into cash: 44.5% vs 15.9%
GILD trades at 19.4x forward earnings, above the sector medianForward p/e, Biotechnology peers
REGN14.3xGILD19.4xABBV19.6xAMGN19.8xBIIB20.5xVRTX29.3xINCY61.0xSector median 19.1xREGN14.3xGILD19.4xABBV19.6xAMGN19.8xBIIB20.5xVRTX29.3xINCY61.0xSector median 19.1x
Source: CNBC quotes; Mostly Markets

Financials

From Gilead Sciences's SEC filings, through the quarter ending 30 Sep 2026. Hover or tap a bar for its value.

Revenue grew 6.8% from a year earlierQuarterly revenue, $bn, latest Q3 ’26
$0bn$2bn$5bn$8bnQ4 ’24Q2 ’25Q4 ’25$8.3bnQ3 ’26$0bn$5bnQ4 ’24Q2 ’25Q4 ’25$8.3bnQ3 ’26
Source: SEC filings
Growth slowed to +6.8% last quarterRevenue growth, year on year, %
0%5%10%Q4 ’24Q2 ’25Q4 ’256.8%Q3 ’260%5%10%Q4 ’24Q2 ’25Q4 ’256.8%Q3 ’26
Source: SEC filings
Operating margin was 41.7% last quarterOperating income as a share of revenue, %
−100%−50%0%Q4 ’24Q2 ’25Q4 ’2541.7%Q3 ’26−100%0%Q4 ’24Q2 ’25Q4 ’2541.7%Q3 ’26
Source: SEC filings
Free cash flow was $13.8 billion over 12 monthsQuarterly free cash flow (operating cash flow minus capex), $bn
$0bn$2bn$4bnQ4 ’24Q2 ’25Q4 ’25$4.8bnQ3 ’26$0bn$2bn$4bnQ4 ’24Q2 ’25Q4 ’25$4.8bnQ3 ’26
Source: SEC filings
Last 12 monthsGILDSector median
Revenue growth+6.5%+7.8%
Gross margin79.9%65.3%
Operating margin−7.6%13.3%
Free cash flow margin44.5%15.9%

Stories on Gilead Sciences

Thursday, 29 October
Earnings

Gilead (GILD) Tops Q3 Estimates as HIV Sales Grow 18%

Gilead's revenue rose 7% to $8.30 billion, beating the $7.81 billion expected, and it raised its 2026 sales forecast. The stock was up 3% after hours.

GILD▲ 4.0%
A scientist at a microscope

Similar companies

Biotechnology, by market value.

CompanyPriceTodayYTDValue
ABBVAbbVie$294.89+1.41%+29.1%$521B
AMGNAmgen$466.01+1.15%+42.4%$252B
VRTXVertex Pharmaceuticals$558.88+3.50%+23.3%$142B
REGNRegeneron Pharmaceuticals$927.89+13.33%+20.2%$95.53B
MRNAModerna$221.72−0.47%+651.8%$88.52B
BIIBBiogen$253.62+1.59%+44.1%$37.49B
INCYIncyte$120.39+3.07%+21.9%$24.40B